Twice-yearly injection cuts HIV risk by 96%, but will cost cut access?

A groundbreaking trial has revealed that a twice-yearly injection of lenacapavir could significantly reduce the risk of HIV infection, offering hope for millions worldwide. Developed by Gilead Sciences, this new HIV prevention method shows an impressive 96% effectiveness, surpassing the daily oral pill, Truvada. However, concerns about cost and access have sparked debates among healthcare […]
Read more

WHO Approves Second Mpox Vaccine For Emergency Use

The World Health Organization (WHO) has approved a second mpox vaccine for emergency use. This vaccine, known as LC16m8, is developed by the Japanese pharmaceutical company KM Biologics. The approval aims to make vaccines more accessible to communities experiencing a surge in mpox outbreaks. Here’s everything you need to know about this significant step in […]
Read more